These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19250790)

  • 1. Complement dependent cytotoxicity (CDC) activity of a humanized anti Lewis-Y antibody: FACS-based assay versus the 'classical' radioactive method -- qualification, comparison and application of the FACS-based approach.
    Nechansky A; Szolar OH; Siegl P; Zinoecker I; Halanek N; Wiederkum S; Kircheis R
    J Pharm Biomed Anal; 2009 May; 49(4):1014-20. PubMed ID: 19250790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualification and application of a surface plasmon resonance-based assay for monitoring potential HAHA responses induced after passive administration of a humanized anti Lewis-Y antibody.
    Szolar OH; Stranner S; Zinoecker I; Mudde GC; Himmler G; Waxenecker G; Nechansky A
    J Pharm Biomed Anal; 2006 Jun; 41(4):1347-53. PubMed ID: 16644171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
    Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function.
    Antes B; Amon S; Rizzi A; Wiederkum S; Kainer M; Szolar O; Fido M; Kircheis R; Nechansky A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):250-6. PubMed ID: 17296336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering.
    Schuster M; Umana P; Ferrara C; Brünker P; Gerdes C; Waxenecker G; Wiederkum S; Schwager C; Loibner H; Himmler G; Mudde GC
    Cancer Res; 2005 Sep; 65(17):7934-41. PubMed ID: 16140965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties.
    Winter J; Barbin K; Bacci C; Bunte T
    J Pharm Biomed Anal; 2011 Jan; 54(1):81-6. PubMed ID: 20828971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.
    Li H; Soroka SD; Taylor TH; Stamey KL; Stinson KW; Freeman AE; Abramson DR; Desai R; Cronin LX; Oxford JW; Caba J; Pleatman C; Pathak S; Schmidt DS; Semenova VA; Martin SK; Wilkins PP; Quinn CP
    J Immunol Methods; 2008 Apr; 333(1-2):89-106. PubMed ID: 18304568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen.
    Farhan H; Schuster C; Klinger M; Weisz E; Waxenecker G; Schuster M; Sexl V; Mudde GC; Freissmuth M; Kircheis R
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1459-66. PubMed ID: 16963623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
    Klehr M; Koehl U; Mühlenhoff M; Tawadros S; Fischer T; Schomäcker K; Heuckmann JM; Bochennek K; Jensen M
    J Immunother; 2009 Jun; 32(5):442-51. PubMed ID: 19609236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
    Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
    Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.
    Westwood JA; Murray WK; Trivett M; Haynes NM; Solomon B; Mileshkin L; Ball D; Michael M; Burman A; Mayura-Guru P; Trapani JA; Peinert S; Hönemann D; Miles Prince H; Scott AM; Smyth MJ; Darcy PK; Kershaw MH
    J Immunother; 2009 Apr; 32(3):292-301. PubMed ID: 19242371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interference.
    McCutcheon KM; Quarmby V; Song A
    J Immunol Methods; 2010 Jun; 358(1-2):35-45. PubMed ID: 20361968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
    Stubenrauch K; Wessels U; Lenz H
    J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins.
    Brasoveanu LI; Maio M
    Scand J Immunol; 1996 Mar; 43(3):351-3. PubMed ID: 8602472
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytotoxicity and antibody binding by flow cytometry: a single assay to simultaneously assess two parameters.
    Saw CL; Bray RA; Gebel HM
    Cytometry B Clin Cytom; 2008 Sep; 74(5):287-94. PubMed ID: 18454488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging.
    Gerritsen AF; Bosch M; de Weers M; de Winkel JG; Parren PW
    J Immunol Methods; 2010 Jan; 352(1-2):140-6. PubMed ID: 19891971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a kinetic assay for analysis of anti-human interleukin-5 monoclonal antibody (SCH 55700) and human interleukin-5 interactions using surface plasmon resonance.
    DiGiacomo RA; Xie L; Cullen C; Indelicato SR
    Anal Biochem; 2004 Apr; 327(2):165-75. PubMed ID: 15051533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision from drug stability studies. Investigation of reliable repeatability and intermediate precision of HPLC assay procedures.
    Ermer J; Arth C; De Raeve P; Dill D; Friedel HD; Höwer-Fritzen H; Kleinschmidt G; Köller G; Köppel H; Kramer M; Maegerlein M; Schepers U; Wätzig H
    J Pharm Biomed Anal; 2005 Jul; 38(4):653-63. PubMed ID: 15967293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A quantitative human monoclonal antibody immunoassay using anti-idiotypic antibody as a membrane antigen surrogate with surface-plasmon-resonance detection.
    Wong RB; Lee AH; Rangan VS; Cheng KC
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):51-61. PubMed ID: 18680480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potency testing of anti-lymphocyte globulins: in vitro alternatives for the monkey skin graft assay.
    Conrad C; Janssen O; Schäffner G; Kabelitz D
    Dev Biol Stand; 1999; 101():113-8. PubMed ID: 10566783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.